• 1. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755

Recent Advances in the Study of 5-Fluoro-2-(3-methoxypropoxy)phenylamine (CAS: 946729-34-6) in Chemical Biology and Pharmaceutical Research

The compound 5-Fluoro-2-(3-methoxypropoxy)phenylamine (CAS: 946729-34-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique structural features, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and mechanisms of action, providing valuable insights into its role as a potential drug candidate or intermediate in medicinal chemistry.

One of the key areas of research has been the optimization of synthetic routes for 5-Fluoro-2-(3-methoxypropoxy)phenylamine. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel, high-yield synthesis method that improves the scalability and purity of the compound. The researchers employed a multi-step process involving fluorination and alkoxylation, achieving an overall yield of 78% with a purity exceeding 99%. This advancement is particularly significant for large-scale pharmaceutical production.

Pharmacological investigations have revealed that 5-Fluoro-2-(3-methoxypropoxy)phenylamine exhibits notable activity as a modulator of specific kinase pathways. In vitro studies demonstrated its inhibitory effects on several cancer-related kinases, with IC50 values in the low micromolar range. These findings suggest potential applications in oncology, particularly for cancers with dysregulated kinase activity. Further in vivo studies are currently underway to evaluate its efficacy and safety profile in animal models.

The compound's unique chemical structure, featuring both fluoro and methoxypropoxy substituents, has been the subject of structure-activity relationship (SAR) studies. Researchers have found that these functional groups contribute significantly to the molecule's binding affinity and selectivity towards target proteins. Computational modeling and X-ray crystallography studies have provided detailed insights into the molecular interactions at atomic resolution, facilitating the design of more potent derivatives.

Recent patent filings (2023-2024) indicate growing commercial interest in 5-Fluoro-2-(3-methoxypropoxy)phenylamine and its derivatives. Several pharmaceutical companies have claimed novel compositions containing this compound for various therapeutic indications, including inflammatory diseases and neurological disorders. These developments highlight the compound's versatility and potential for multiple medical applications.

Ongoing research is exploring the compound's potential in drug combination therapies. Preliminary results suggest synergistic effects when 5-Fluoro-2-(3-methoxypropoxy)phenylamine is administered with certain chemotherapeutic agents, potentially allowing for reduced dosages and minimized side effects. Clinical translation of these findings, however, will require extensive preclinical testing and regulatory approval processes.

In conclusion, 5-Fluoro-2-(3-methoxypropoxy)phenylamine (CAS: 946729-34-6) represents a promising chemical entity in pharmaceutical research. Recent advances in its synthesis, mechanistic understanding, and therapeutic potential position it as a compound worthy of continued investigation. Future research directions may include further optimization of its pharmacokinetic properties, expansion of its therapeutic indications, and exploration of novel formulations for enhanced delivery and efficacy.

• 1978-39-8(5-Fluoro-2-methoxyaniline)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)